Any news on advancements in osteoarthritis disease treatments or medication
Community
HealthYour question
Any news on advancements in osteoarthritis disease treatments or medication
AI search focus (disambiguated)
Recent news and announcements regarding medical advancements, clinical trial breakthroughs, or NHS and NICE approvals for new osteoarthritis treatments and medications. (Assumed: Included NICE (National Institute for Health and Care Excellence) alongside the NHS, as NICE is the regulatory body that approves new treatments for NHS use in the UK.)
Tags
Update found
Review the latest finding below. Monitoring keeps running; you’ll be notified again if something materially changes. Stop monitoring when you no longer want alerts.
Latest from the web
Between 20 and 22 June 2026, several significant clinical updates for osteoarthritis were reported, including five-year data showing that sprifermin injections can sustain knee cartilage thickness and potentially prevent the need for joint replacements. New research published on 22 June also highlighted the superior efficacy of platelet-rich plasma (PRP) injections over traditional corticosteroids for advanced cases, alongside a breakthrough study on low-intensity ultrasound therapy for tissue repair. Additionally, Cynata Therapeutics held a follow-up webinar on 21 June to address the recent failure of its Phase 3 stem cell trial, which has left the medical community seeking alternative regenerative options.
- Sprifermin 5-Year Trial Results: On 20 June 2026, long-term results from the FORWARD trial confirmed that 100 μg doses of sprifermin sustained femorotibial joint cartilage thickness for five years, with no patients in the high-dose group requiring knee replacement surgery.
- PRP vs. Corticosteroids Study: A randomized trial reported on 22 June 2026 found that two platelet-rich plasma (PRP) injections provided significantly better pain relief and functional improvement over six months than corticosteroids or oral NSAIDs for patients with advanced knee osteoarthritis.
- Ultrasound Therapy for Joint Healing: On 22 June 2026, researchers from the University of Alabama in Huntsville published a study in Scientific Reports showing that continuous low-intensity ultrasound can shift the immune response toward tissue repair and reduce chronic inflammation in osteoarthritis.
- Cynata Therapeutics Trial Webinar: On 21 June 2026, Cynata Therapeutics held a webinar to discuss the 'shock' failure of its Phase 3 SCUlpTOR trial, confirming that the stem-cell treatment failed to meet primary endpoints for pain and cartilage preservation.
- WhartoCell Authorization: On 21 June 2026, the Iranian Food and Drug Administration authorized 'WhartoCell,' a new umbilical cord-derived stem cell product, for clinical use in treating osteoarthritis and promoting cartilage regeneration.
Monitoring stays on automatically. Clear highlight when you’re done reading (optional). Snooze or stop monitoring below if you prefer.